Cvs Health Corp Stock Price, News & Analysis

Zydus Lifesciences has announced an agreement with CVS Caremark to include its diabetes medications Zituvio™, Zituvimet™, and Zituvimet™ XR in CVS's template formulary starting January 1, 2025. These products, containing sitagliptin and metformin hydrochloride, are approved by the FDA through the 505(b)(2) route for improving glycemic control in adults with type 2 diabetes mellitus.

The medications work through DPP-4 inhibition and as biguanides, serving as an adjunct to diet and exercise. According to IQVIA™ data (MAT Aug-2023), the U.S. market for DPP-IV inhibitors and their combinations is valued at US$ 10 billion. This partnership represents a significant opportunity for Zydus to expand its presence in the U.S. market with its differentiated product portfolio.

CVS Health has announced that all commercial prescriptions at CVS Pharmacy will now be reimbursed through their new CVS CostVantage model starting this year. This innovative reimbursement approach uses a transparent formula based on drug acquisition cost, a set markup, and a service fee reflecting pharmacy service quality.

The model aims to transform pharmacy reimbursement by removing market reliance on cross-subsidization and providing greater clarity in pricing. According to recent survey data, 81% of consumers trust their local pharmacist, and 88% view pharmacists as their most accessible healthcare providers, with nearly 1 in 3 Americans visiting pharmacies weekly—twice as often as physician visits.

The initiative represents a strategic shift towards more sustainable retail pharmacy services, with plans to eventually expand to Medicare and Medicaid managed prescriptions. This new approach helps reduce the need for higher rates on some medicines to subsidize losses on others, while providing enhanced transparency for PBMs and payors.

CVS Health (NYSE: CVS) has announced its board of directors has approved a quarterly dividend of $0.665 per share on the Common Stock. The dividend will be paid on February 3, 2025, to shareholders of record as of January 23, 2025.

Varo Bank has announced a collaboration with Green Dot and CVS Health to enable zero-fee cash deposits for its customers at over 7,500 participating CVS Pharmacy locations nationwide. This service could save customers who regularly deposit cash approximately $120 or more annually.

The initiative leverages Green Dot's embedded finance platform (Arc) and money movement network. As the first all-digital nationally chartered bank in the U.S., Varo offers various fee-free banking services including no monthly fees, minimum balance requirements, transfer fees, or overdraft fees. Additional benefits include free withdrawals at 40,000+ Allpoint® ATMs, 2-day early payday with direct deposits, automatic cash back rewards, and eligibility for Varo Advance and Line of Credit services.

Aetna, a CVS Health company, has enhanced its Aetna Health app with Spanish language capabilities, making it accessible to all eligible health plan members. The update includes Spanish translations for identity cards, benefit details, deductibles, claims, cost estimates, and healthcare provider information.

The initiative aims to improve navigation, health literacy, and care access for Spanish-speaking members. Aetna also provides Spanish-speaking care managers and customer service representatives, while conducting community outreach through events and broadcast interviews to share public health information in Spanish.

The company plans to explore expanding language capabilities further to serve its diverse member population.

CVS Health has announced the pricing details of its Maximum Tender Offer for multiple series of Senior Notes, with a maximum purchase price of $1,774,423,242.62. The tender offer includes various series of notes with maturities ranging from 2030 to 2050. Notes tendered by the Early Tender Date of December 13, 2024, will receive the Total Consideration, which includes the Early Tender Payment of $30 per $1,000 principal amount.

The settlement date for notes validly tendered by the Early Tender Date is expected to be December 18, 2024. Due to oversubscription at the Early Tender Date, no notes tendered after this date are expected to be accepted for purchase. The 2.700% Senior Notes due 2040, 3.875% Senior Notes due 2047, and 4.250% Senior Notes due 2050 will be accepted at 100% proration, while the 4.125% Senior Notes due 2040 will be accepted at 57.5% proration.

CVS Health announced early results of its cash tender offer for multiple series of senior notes, with a maximum purchase price of $1.77 billion. The tender offer includes ten different series of notes with various interest rates and maturities ranging from 2030 to 2050. As of December 13, 2024, significant portions of various notes have been tendered, with participation rates ranging from 14.56% to 70.61%.

The company will settle the tender offer early on December 18, 2024. The total consideration will be calculated based on U.S. Treasury yields plus fixed spreads, and includes an early tender payment of $30 per $1,000 principal amount. Due to reaching the maximum tender amount, no additional notes will be purchased after the early settlement date.

CVS Health announced the results of its cash tender offer for its 4.100% Senior Notes due 2025. As of December 6, 2024, $225,979,000 in principal amount was validly tendered, with an additional $5,000 tendered under guaranteed delivery procedures. The settlement date is expected to be December 11, 2024.

The company plans to fund the purchase using proceeds from its newly issued 7.000% Series A Junior Subordinated Notes due 2055 and 6.750% Series B Junior Subordinated Notes due 2054. CVS Health expects to accept all validly tendered notes for purchase.

This tender offer is part of a larger initiative that includes a Maximum Tender Offer with a maximum purchase price of $2,000,000,000, less the amount paid for the Any and All Notes.

CVS Health has announced pricing details for its cash tender offer for all outstanding 4.100% Senior Notes due 2025. The total consideration is $998.22 per $1,000 principal amount of notes, with a reference yield of 4.434%. The tender offer expires at 5:00 p.m., New York City time, on December 6, 2024.

The settlement date is expected to be December 11, 2024. Holders will receive accrued and unpaid interest in addition to the total consideration. The offer affects $950,087,000 in outstanding notes. Holders can withdraw tendered notes until the withdrawal deadline of 5:00 p.m., December 6, 2024.

The tender offer is not conditioned on minimum participation but is subject to a financing condition and other general conditions.